Cash for new phase 3 | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email

IMGN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49460 of 50795  at  5/16/2019 7:48:34 AM  by


Cash for new phase 3

Enyedy sounded quite angry on the call. I believe they truly felt they have worked closely with the fda and deserved better based on precedents, compelling data for high and unmet need.

In any event they are grin and bearing the result and ready to move on. New phase 3 is the plan and the major questions were when start, what is anticipated costs and can they afford it.

Enyedy said they have more than sufficient cash for trial.

Expect trial to start this year in which he said would have a high probability of success

Enyedy said they will do a corporate review.

So I think the forward 2 combo trials complete that will be it. Perhaps they will sell off license in some of the early partnerships or wait to see results from ASH and discuss opt in with Jazz.

They may also do a rest of world deal and have that partner fund the study. I doubt it though as imgn should be greedy on the potential 1.6 billion in sales for the high folate EOC patients.

In any event, it is a major setback in their ability to generate any consistent revenues.

Who knows, they could also just outright sell the company but that most likely wouldn’t happen until ASH data released.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 249
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
49461 Re: Cash for new phase 3 jv08201 0 5/16/2019 8:12:13 AM
49463 Re: Cash for new phase 3 golfingarmyofone 1 5/16/2019 9:42:12 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by